Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …

Amyloid β protein (Aβ) is the main component of neuritic plaques in Alzheimer's disease
(AD), and its accumulation has been considered as the molecular driver of Alzheimer's …

Alzheimer's disease has a higher incidence in older women, with a spike in cognitive
decline that tracks with visceral adiposity, dysregulated energy homeostasis and bone loss …

Synaptic abnormalities are a cardinal feature of Alzheimer's disease (AD) that are known to
arise as the disease progresses. A growing body of evidence suggests that pathological …

Abstract Alzheimer's disease (AD), the most common cause of dementia, results in a
sustained decline in cognition. There are currently few effective disease modifying therapies …

Microglia are the resident macrophages of the central nervous system (CNS) acting as the
first line of defense in the brain by phagocytosing harmful pathogens and cellular debris …

Protein misfolding and aggregation is observed in many amyloidogenic diseases affecting
either the central nervous system or a variety of peripheral tissues. Structural and dynamic …

A reduced removal of dysfunctional mitochondria is common to aging and age-related
neurodegenerative pathologies such as Alzheimer's disease (AD). Strategies for treating …

Patients with Alzheimer's disease (AD) present with both extracellular amyloid-β (Aβ)
plaques and intracellular tau-containing neurofibrillary tangles in the brain. For many years …

Epigenetic regulatory mechanisms, including DNA methylation, histone modification,
chromatin remodeling, and microRNA expression, play critical roles in cell differentiation …